Episode Details

Legend Biotech just slammed into a new 52-week low, plunging 11% after missing sales estimates for its flagship cancer drug, Carvykti. Wall Street’s reaction was brutal—with analysts slashing price targets from $62 to $21—but management is standing firm on its $3 billion forecast. Is this a disastrous sign of stalling demand, or does the crash make Legend a bargain buyout target for Big Pharma? In this episode, we break down the numbers to see if this is a value trap or a golden opportunity in the cell therapy space.